{"nctId":"NCT05282004","briefTitle":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit","startDateStruct":{"date":"2022-05-16","type":"ACTUAL"},"conditions":["Neovascular Age-related Macular Degeneration (nAMD)"],"count":36,"armGroups":[{"label":"SOK583A1","type":"EXPERIMENTAL","interventionNames":["Drug: SOK583A1"]}],"interventions":[{"name":"SOK583A1","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients ≥ 50 years of age at baseline\n* Patients diagnosed with nAMD (uni- or bilateral)\n* Patients already under IVT Eylea treatment (last injection of the induction period or maintenance phase)\n* Willing and able to comply with all study procedures, and be likely to complete the study\n* Signed informed consent must be obtained before any assessment is performed\n\nExclusion Criteria:\n\n* Active, suspected or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or autoimmune associated uveitis or endophthalmitis\n* Any uncontrolled ocular hypertension or glaucoma in the study eye (defined as IOP ≥ 26 mmHg, despite treatment with anti-glaucomatous medication)\n* History of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of investigational product\n* Visual acuity Score (VAS) worse than 20/200 on a Snellen chart, the generally accepted level of legal blindness\n* Topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening\n* Systemic treatment with long-acting corticosteroids (more than 10 mg prednisolone equivalent) within 3 months prior to screening Current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol\n* Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye any time during the past 3 months\n* Receipt of any systemic anti-VEGF within the last 6 months prior to enrollment\n* Uncontrolled hypertension (defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening)\n* Participants who do not comply with the local COVID-19 regulations of the study site","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Ocular Treatment Emergent Adverse Events","description":"Number of participants with ocular treatment emergent adverse events were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Non-ocular Treatment Emergent Adverse Events","description":"Number of participants with non-ocular treatment emergent adverse events were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":36},"commonTop":["Intraocular pressure increased","Conjunctival haemorrhage","Vitreous floaters","COVID-19"]}}}